These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
408 related articles for article (PubMed ID: 25717238)
1. Mechanism of action of gypenosides on type 2 diabetes and non-alcoholic fatty liver disease in rats. He Q; Li JK; Li F; Li RG; Zhan GQ; Li G; Du WX; Tan HB World J Gastroenterol; 2015 Feb; 21(7):2058-66. PubMed ID: 25717238 [TBL] [Abstract][Full Text] [Related]
2. Hepatoprotective and antioxidant effects of lycopene on non-alcoholic fatty liver disease in rat. Jiang W; Guo MH; Hai X World J Gastroenterol; 2016 Dec; 22(46):10180-10188. PubMed ID: 28028366 [TBL] [Abstract][Full Text] [Related]
4. Protective effects of gypenosides against fatty liver disease induced by high fat and cholesterol diet and alcohol in rats. Qin R; Zhang J; Li C; Zhang X; Xiong A; Huang F; Yin Z; Li K; Qin W; Chen M; Zhang S; Liang L; Zhang H; Nie H; Ye W Arch Pharm Res; 2012 Jul; 35(7):1241-50. PubMed ID: 22864747 [TBL] [Abstract][Full Text] [Related]
5. Structural modulation of gut microbiota during alleviation of non-alcoholic fatty liver disease with Gynostemma pentaphyllum in rats. Shen SH; Zhong TY; Peng C; Fang J; Lv B BMC Complement Med Ther; 2020 Feb; 20(1):34. PubMed ID: 32024509 [TBL] [Abstract][Full Text] [Related]
6. Effect of nuclear factor-κB and angiotensin II receptor type 1 on the pathogenesis of rat non-alcoholic fatty liver disease. Tan DY; Shi HY; Li CP; Zhong XL; Kang M World J Gastroenterol; 2015 May; 21(19):5877-83. PubMed ID: 26019451 [TBL] [Abstract][Full Text] [Related]
7. Ameliorative effects of lutein on non-alcoholic fatty liver disease in rats. Qiu X; Gao DH; Xiang X; Xiong YF; Zhu TS; Liu LG; Sun XF; Hao LP World J Gastroenterol; 2015 Jul; 21(26):8061-72. PubMed ID: 26185377 [TBL] [Abstract][Full Text] [Related]
8. [Effect of targeted inhibition of hypoxia-inducible factor-1α by 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole on the progression of non-alcoholic fatty liver disease in rats]. Shen WD; Zhang W; Xu QH; Liu PF Zhonghua Gan Zang Bing Za Zhi; 2016 Oct; 24(10):749-754. PubMed ID: 27938560 [No Abstract] [Full Text] [Related]
9. Ameliorative effect of nicorandil on high fat diet induced non-alcoholic fatty liver disease in rats. Elshazly SM Eur J Pharmacol; 2015 Feb; 748():123-32. PubMed ID: 25542756 [TBL] [Abstract][Full Text] [Related]
10. [Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats]. Zhang DM; Zhang GY; Wang T; Zhong HJ; Chen WK Zhonghua Yi Xue Za Zhi; 2006 May; 86(18):1279-83. PubMed ID: 16796890 [TBL] [Abstract][Full Text] [Related]
11. Protective effect and mechanism of Qiwei Tiexie capsule on 3T3-L1 adipocytes cells and rats with nonalcoholic fatty liver disease by regulating LXRα, PPARγ, and NF-κB-iNOS-NO signaling pathways. Suolang PC; Liu BQ; Chen J; De J; Nima ZB; Dunzhu CR J Ethnopharmacol; 2019 May; 236():316-325. PubMed ID: 30851372 [TBL] [Abstract][Full Text] [Related]
12. The Chinese medicine Chai Hu Li Zhong Tang protects against non-alcoholic fatty liver disease by activating AMPKα. Zhang M; Yuan Y; Wang Q; Li X; Men J; Lin M Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30291215 [TBL] [Abstract][Full Text] [Related]
13. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue. Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472 [TBL] [Abstract][Full Text] [Related]
14. [Effects of celecoxib on expression of PPARγ and NF-κB in type 2 diabetes rats with non-alcoholic steatohepatitis]. Tian F; Zhang YJ; Wang YH Zhonghua Gan Zang Bing Za Zhi; 2016 Aug; 24(8):590-595. PubMed ID: 27788706 [No Abstract] [Full Text] [Related]
15. Protective Effects of Chaihu Shugan San () on Nonalcoholic Fatty Liver Disease in Rats with Insulin Resistance. Jiang WN; Li D; Jiang T; Guo J; Chen YF; Wang J; Zhou Y; Yang CY; Tang CP Chin J Integr Med; 2018 Feb; 24(2):125-132. PubMed ID: 27164963 [TBL] [Abstract][Full Text] [Related]
16. Pioglitazone ameliorates nonalcoholic steatohepatitis by down-regulating hepatic nuclear factor-kappa B and cyclooxygenases-2 expression in rats. Zhao JS; Zhu FS; Liu S; Yang CQ; Chen XM Chin Med J (Engl); 2012 Jul; 125(13):2316-21. PubMed ID: 22882855 [TBL] [Abstract][Full Text] [Related]
17. [Effect of apigenin on protein expressions of PPARs in liver tissues of rats with nonalcoholic steatohepatitis]. Shi T; Zhuang R; Zhou H; Wang F; Shao Y; Cai Z Zhonghua Gan Zang Bing Za Zhi; 2015 Feb; 23(2):124-9. PubMed ID: 25880979 [TBL] [Abstract][Full Text] [Related]
18. Involvement of hepatic peroxisome proliferator-activated receptor α/γ in the therapeutic effect of osthole on high-fat and high-sucrose-induced steatohepatitis in rats. Zhao X; Xue J; Wang XL; Zhang Y; Deng M; Xie ML Int Immunopharmacol; 2014 Sep; 22(1):176-81. PubMed ID: 24993341 [TBL] [Abstract][Full Text] [Related]
19. Genistein can ameliorate hepatic inflammatory reaction in nonalcoholic steatohepatitis rats. Yin Y; Liu H; Zheng Z; Lu R; Jiang Z Biomed Pharmacother; 2019 Mar; 111():1290-1296. PubMed ID: 30841442 [TBL] [Abstract][Full Text] [Related]
20. Paeoniflorin alleviates non-alcoholic steatohepatitis in rats: Involvement with the ROCK/NF-κB pathway. Ma Z; Chu L; Liu H; Li J; Zhang Y; Liu W; Dai J; Yi J; Gao Y Int Immunopharmacol; 2016 Sep; 38():377-84. PubMed ID: 27351828 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]